Physician profile
Juan E Sanchez
NPI 1447298633
$18,102.89
in general payments reported to CMS, 2019-2025
75 companies · $5,004 in 2025
The $5,004 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,412 · 2020: $915 · 2021: $2,161 · 2022: $2,157 · 2023: $2,577 · 2024: $2,878 · 2025: $5,004.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,938 · Long Term Medical Supply Or Device Loan: $299 · Education: $221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,938.17 |
| Long Term Medical Supply Or Device Loan | $299.10 |
| Education | $221.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,853.38 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,236.70 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Incyte Corporation | $916.29 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Pfizer INC. | $903.18 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $795.69 | 2019-2025 | Fruzaqla, Ninlaro, Alunbrig |
| E.R. Squibb & Sons, L.L.C. | $785.21 | 2019-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $731.64 | 2019-2025 | Rybrevant, Erleada, Darzalex |
| Eisai INC. | $721.81 | 2019-2025 | |
| Lilly USA, LLC | $701.99 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Celgene Corporation | $660.78 | 2019-2025 | Reblozyl, Opdualag, Opdivo |
| Merck Sharp & Dohme LLC | $543.67 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Karyopharm Therapeutics INC. | $533.22 | 2021-2025 | Xpovio |
| Genzyme Corporation | $474.57 | 2019-2025 | |
| Glaxosmithkline, LLC. | $444.33 | 2020-2025 | Zejula, Ojjaara, Jemperli |
| Astellas Pharma US INC | $430.49 | 2022-2025 | Vyloy, Xtandi, Xospata |
Show all 75 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $329.23 | 2021-2025 | Bavencio |
| Daiichi Sankyo INC. | $323.76 | 2020-2025 | Enhertu, Vanflyta, Datroway |
| Abbvie INC. | $317.96 | 2019-2025 | |
| Seagen INC. | $287.17 | 2019-2023 | Adcetris, Tukysa |
| Genentech USA, INC. | $264.16 | 2019-2025 | Venclexta, Tecentriq, Itovebi |
| Bayer Healthcare Pharmaceuticals INC. | $248.03 | 2019-2024 | |
| Exelixis INC. | $240.83 | 2019-2025 | Cabometyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.57 | 2019-2025 | Gilotrif |
| Array Biopharma INC | $222.20 | 2022-2025 | Mektovi, Braftovi, Lorbrena |
| Amgen INC. | $216.23 | 2019-2023 | Lumakras, Nplate, Xgeva |
| Regeneron Healthcare Solutions, INC. | $209.68 | 2023-2025 | Libtayo |
| Beigene USA, INC. | $200.11 | 2022-2025 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $196.31 | 2021-2023 | Imbruvica |
| Tersera Therapeutics LLC | $192.61 | 2021-2025 | Zoladex, Xermelo |
| Sobi, INC | $181.92 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $178.96 | 2023-2025 | Tazverik, Onivyde |
| Puma Biotechnology, INC. | $173.79 | 2021-2025 | |
| Rigel Pharmaceuticals, INC. | $173.06 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Stemline Therapeutics INC. | $164.69 | 2023-2025 | Orserdu |
| Blueprint Medicines Corporation | $134.48 | 2020-2025 | Ayvakit |
| Genmab U.S., INC. | $121.46 | 2023-2024 | Epkinly |
| Agios Pharmaceuticals, INC. | $115.02 | 2024-2025 | Pyrukynd |
| Taiho Oncology, INC. | $107.98 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $105.73 | 2019-2024 | Ultomiris |
| Pharmaessentia USA Corporation | $105.28 | 2023-2025 | Besremi |
| Kite Pharma, INC. | $103.61 | 2020-2022 | |
| Tolmar Pharmaceuticals, INC. | $101.26 | 2019-2022 | |
| Blue Earth Diagnostics | $75.94 | 2021-2023 | |
| Tesaro, INC. | $67.76 | 2019 | |
| Ge Healthcare | $66.71 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $58.83 | 2019-2020 | |
| Beone Medicines USA, INC. | $55.36 | 2025 | Brukinsa |
| Clovis Oncology, INC. | $53.65 | 2019 | |
| Shield Therapeutics INC | $53.08 | 2025 | |
| Sun Pharmaceutical Industries INC. | $52.11 | 2022 | |
| Servier Pharmaceuticals LLC | $47.29 | 2025 | |
| Morphosys, US INC. | $47.25 | 2021-2023 | Monjuvi |
| Tempus Ai, INC | $41.95 | 2024 | Xt Cdx |
| Iovance Biotherapeutics, INC. | $39.45 | 2025 | Amtagvi |
| Janssen Scientific Affairs, LLC | $29.29 | 2019 | |
| Gilead Sciences, INC. | $28.03 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $27.87 | 2025 | Danziten |
| Sumitomo Pharma America, INC. | $24.39 | 2025 | Orgovyx |
| Springworks Therapeutics, INC. | $24.32 | 2024 | Ogsiveo |
| Recordati_rare_diseases_inc. | $23.90 | 2025 | Enjaymo |
| Amag Pharmaceuticals, INC. | $23.69 | 2021 | |
| Deciphera Pharmaceuticals INC. | $23.53 | 2025 | Qinlock, Romvimza |
| Mylan Institutional INC. | $23.10 | 2019 | |
| Jazz Pharmaceuticals INC. | $22.96 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $22.95 | 2019 | |
| Novocure INC. | $22.40 | 2025 | Optune Lua (Novottf-200t) |
| Accord Healthcare, INC. | $22.21 | 2025 | |
| Dendreon Pharmaceuticals LLC | $22.00 | 2019 | |
| Tolmar, INC. | $21.51 | 2023 | |
| Alnylam Pharmaceuticals INC. | $20.96 | 2023 | Onpattro |
| Dova Pharmaceuticals | $18.45 | 2021 | |
| Mirati Therapeutics, INC. | $17.75 | 2024 | Krazati |
| Epizyme, INC. | $17.41 | 2022 | |
| Acceleron Pharma, INC. | $17.17 | 2021 | |
| Apellis Pharmaceuticals, INC. | $16.58 | 2025 | Empaveli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.